aTyr Pharma, Inc. is a clinical-stage biotechnology company. Co. is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. We show 7 historical shares outstanding datapoints in our ATYR shares outstanding history coverage, used to compute ATYR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATYR market cap history over the course of time is important for investors
interested in comparing ATYR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATYR versus a peer is one thing; comparing
ATYR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATYR can fluctuate over the course of history.
With this page we aim to empower investors researching ATYR by allowing them to research the ATYR market cap history. |
Free ATYR Email Alerts:
Video: The Importance of Market Cap
